The Bayer Pharma Data Science & Artificial Intelligence (DS&AI) F2F meeting in Madrid was a great event! The motto Connect, Clarify & Commit came to life as we connected during networking sessions, breakout sessions and social events. At the poster session we learned about our progress embedding a product mindset and driving operational excellence, closely collaborating with our partners across R&D. We heard presentations, took part in discussions, unconference sessions, asked questions and shared ideas, setting foundations for the growth of DS&AI beyond 2023. The use of POAPs was a definite social success and I am sure you did not miss Jesús’ enthusiasm as he gave an overview of this new tool. By promoting its use, we drive new ways of using this sustainable and effective tool, ultimately helping to innovate its use by doctors, within clinical trials, for patients and more. There were fun elements as well, like the final night, where our very own flash-mob took to the dance floor and we danced until way past midnight! All this was made possible by the org team: Anke Ebert, Larsen Schnadhorst, Kathleen Thies, Sheila Elz, Stefanie Holt-Noreiks and Claudia Vogt. They have done an excellent job coordinating the event, with the perfect balance of presentations, speakers, entertainment, and networking. Now let us make sure we continue to further the impact we have on bringing innovative medicines to our patients. Sai Jasti, Head of DS&AI https://bayer.com/poap

With the aim of protecting more and more Greek patients, a new product in Cardiovascular Medicine is launched. KERENDIA is now available for patients with CKD & Type 2 Diabetes. Welcome to Bayer Hellas internal Kerendia launch event, focusing on educating & preparing the Sales Team for a successful product promotion in the Greek market. In this event, you familiarized yourselves with the promotional materials & the role plays. This is the first POAP related to a pharmaceutical product. If you received this POAP, you are a True Pioneer in the Web3 space. Bayer is proudly promoting innovative practices. https://www.bayer.com/en/poap-tc

Experienced leader in development, validation, and implementation of clinical trial software and processes

I met Jesus during the Bayer Data Science & Artificial Intelligence, DS&AI, F2F event in Madrid in May 2023. Jesus works at Bayer AG currently as the Head of Business Disruption. If you are into Stranger Things, Breakthrough Innovations, AcceleRed, TeamRed, Science4Berlin, STEM4Health, Hackathons, Biotech, Digital Health, Startups, Entrepreneurship, Intrapreneurship, Web3, Web5, Networking For Health, Science, Technology, Pharma, Exobiology, Space, Science Fiction, Germany, Cuba, you can connect with Jesus in LinkedIn: https://www.linkedin.com/in/yeysus/ Twitter: https://twitter.com/yeysus Meetup: https://www.meetup.com/members/45080772/ Web3: yeysus.eth/.tez/.near Some of his POAPs collections in Welook.io: Bayer: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/1 Corporates: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/2 Animated: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/5 Ladies: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/8 Beautiful: https://welook.io/0x74839F2fF3bb6F98E5f120329A76A89f52b95DCC/poap/c/9 Great connecting with you!

Hubble is a pioneering data hub that continuously integrates and enriches terabytes of external scientific textual data to support insight generation along the R&D value chain. It opens opportunities for statistical analyses, large-scale text-mining and other data science methodologies to tease out important details and detect trends within e.g., patents, scientific literature, and grants. The Hubble platform is available Bayer-wide, and offers API access for data scientists. This allows large scale, programmatic analysis as well as integration into processes and platforms. Hubble is a cornerstone of our digital transformation journey within R&D. It serves many users, systems and processes with key data & analyses by answering ~2 million queries per week. We continue to extend the platform to best support insight generation and scientific decision making with a precision medicine focus. For more information contact: Astrid Rheinländer.